688331 荣昌生物
已收盘 04-25 15:00:00
资讯
新帖
简况
荣昌生物04月25日获主力加仓1697万元
市场透视 · 04-25 07:21
荣昌生物04月25日获主力加仓1697万元
荣昌生物获得上百家机构调研，核心管线开发进展成关注焦点
动脉网 · 04-25 06:19
荣昌生物获得上百家机构调研，核心管线开发进展成关注焦点
荣昌生物04月24日主力净流入3785万元 散户资金抛售
市场透视 · 04-24 07:20
荣昌生物04月24日主力净流入3785万元 散户资金抛售
荣昌生物：多项成果股价涨 8.50%
和讯网 · 04-24 04:21
荣昌生物：多项成果股价涨 8.50%
港股异动 | 荣昌生物(09995)一度涨超12% 维迪西妥单抗一线治疗胃癌结果入选2025 ASCO口头报告
智通财经网 · 04-24 03:11
港股异动 | 荣昌生物(09995)一度涨超12% 维迪西妥单抗一线治疗胃癌结果入选2025 ASCO口头报告
荣昌生物(09995)上涨10.76%，报39.1元/股
金融界 · 04-24 01:54
荣昌生物(09995)上涨10.76%，报39.1元/股
【港股创新药板块盘初拉升，凯莱英涨超9%】港股创新药板块盘初拉升，凯莱英涨超9%，荣昌生物涨超7%，信达生物、君实生物、康龙化成纷纷上扬。
金融界 · 04-24 01:41
【港股创新药板块盘初拉升，凯莱英涨超9%】港股创新药板块盘初拉升，凯莱英涨超9%，荣昌生物涨超7%，信达生物、君实生物、康龙化成纷纷上扬。
荣昌生物涨5% 近半年6家券商买入
智选洞察 · 04-24 01:36
荣昌生物涨5% 近半年6家券商买入
2025 ASCO｜荣昌生物维迪西妥单抗一线治疗胃癌结果入选口头报告
荣昌生物 · 04-24 00:30
2025 ASCO｜荣昌生物维迪西妥单抗一线治疗胃癌结果入选口头报告
【港股医药股走强 歌礼制药涨近18%】截至发稿，歌礼制药-B(01672.HK)涨17.81%、荣昌生物(09995.HK)涨10.06%、映恩生物-B(09606.HK)涨9%、来凯生物-B(02105.HK)涨8.25%。
金融界 · 04-22
【港股医药股走强 歌礼制药涨近18%】截至发稿，歌礼制药-B(01672.HK)涨17.81%、荣昌生物(09995.HK)涨10.06%、映恩生物-B(09606.HK)涨9%、来凯生物-B(02105.HK)涨8.25%。
港股创新药板块走强，歌礼制药(01672.HK)涨超20%，荣昌生物(09995.HK)、石药集团(01093.HK)涨
美港电讯 · 04-22
港股创新药板块走强，歌礼制药(01672.HK)涨超20%，荣昌生物(09995.HK)、石药集团(01093.HK)涨
荣昌生物涨5% 无CDMO业务计划
智选洞察 · 04-21
荣昌生物涨5% 无CDMO业务计划
荣昌生物：没有开展CDMO业务的计划
格隆汇 · 04-18
荣昌生物：没有开展CDMO业务的计划
荣昌生物：对于您提及的ADC联合疗法目前公司针对RC48与PD-1抑制剂的联合疗法已有适应症启动全球多中心临床研究
证券之星 · 04-18
荣昌生物：对于您提及的ADC联合疗法目前公司针对RC48与PD-1抑制剂的联合疗法已有适应症启动全球多中心临床研究
荣昌生物：公司会定期对研发管线进行全面评估
证券之星 · 04-18
荣昌生物：公司会定期对研发管线进行全面评估
荣昌生物：公司将通过提高研发效率，平衡研发投入与盈利目标
证券之星 · 04-18
荣昌生物：公司将通过提高研发效率，平衡研发投入与盈利目标
荣昌生物收盘下跌1.07%，最新市净率12.45，总市值247.24亿元
金融界 · 04-17
荣昌生物收盘下跌1.07%，最新市净率12.45，总市值247.24亿元
荣昌生物04月16日主力净流出3220万元 散户资金买入
市场透视 · 04-16
荣昌生物04月16日主力净流出3220万元 散户资金买入
港股异动 | 荣昌生物(09995)再涨超4% 月底将披露一季度业绩 泰它西普三期MG数据积极
智通财经 · 04-16
港股异动 | 荣昌生物(09995)再涨超4% 月底将披露一季度业绩 泰它西普三期MG数据积极
荣昌生物大跌5% 近半年6家券商买入
智选洞察 · 04-16
荣昌生物大跌5% 近半年6家券商买入
加载更多
公司概况
公司名称：
荣昌生物制药(烟台)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-31
主营业务：
荣昌生物制药(烟台)股份有限公司的主营业务是开发与商业化创新、有特色的同类首创（first-in-class）与同类最佳（best-in-class）生物药，以创造药物临床价值为导向，为自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域提供安全、有效、可及的临床解决方案，以满足大量尚未被满足的临床需求。公司的主要产品是泰它西普（RC18）、维迪西妥单抗（RC48）、RC28、RC88、RC148、RC278。
发行价格：
48.00
{"stockData":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":52.06,"timestamp":1745564400000,"preClose":51.3,"halted":0,"volume":6658793,"delay":0,"changeRate":0.0148,"floatShares":162000000,"shares":544000000,"eps":-2.6188,"marketStatus":"已收盘","change":0.76,"latestTime":"04-25 15:00:00","open":52,"high":53.14,"low":49.85,"amount":344000000,"amplitude":0.0641,"askPrice":52.06,"askSize":10,"bidPrice":52,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-2.6188,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745803800000},"marketStatusCode":5,"adr":0,"adjPreClose":51.3,"symbolType":"stock_kcb","openAndCloseTimeList":[[1745544600000,1745551800000],[1745557200000,1745564400000]],"highLimit":56.43,"lowLimit":46.17,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":544332083,"isCdr":false,"pbRate":14.27,"roa":"--","roe":"--","epsLYR":-2.73,"committee":-0.48913,"marketValue":28338000000,"turnoverRate":0.0411,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-04-28。","afterMarket":{"amount":0,"volume":0,"close":52.06,"buyVolume":0,"sellVolume":0,"time":1745566438029,"indexStatus":"已收盘 04-25 15:30:00","preClose":51.3},"hkstockBrief":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":43.45,"timestamp":1745568503021,"preClose":41.35,"halted":0,"volume":13048268,"delay":0,"premium":"-21.60"},"floatMarketCap":8431000000},"requestUrl":"/m/hq/s/688331","defaultTab":"news","newsList":[{"id":"2530977972","title":"荣昌生物04月25日获主力加仓1697万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530977972","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530977972?lang=zh_cn&edition=full","pubTime":"2025-04-25 15:21","pubTimestamp":1745565685,"startTime":"0","endTime":"0","summary":"04月25日, 荣昌生物股价涨1.48%，报收52.06元，成交金额3.44亿元，换手率4.11%，振幅6.41%，量比1.26。荣昌生物今日主力资金净流入1697万元，上一交易日主力净流入3785万元。|04月25日主力加仓幅度排名||#|股票简称|主力净额占比|#|N众捷汽车|25.80%|#|天元智能|12.79%|#|九洲集团|10.34%|#|...|...|#562|荣昌生物|0.20%|荣昌生物所在的生物制品行业，今日主力净流入1.72亿元，行业排名21/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425161756a6c7bdcd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425161756a6c7bdcd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064130708.USD","LU2148510915.USD","LU1064131003.USD","688331","BK0239"],"gpt_icon":0},{"id":"2530192286","title":"荣昌生物获得上百家机构调研，核心管线开发进展成关注焦点","url":"https://stock-news.laohu8.com/highlight/detail?id=2530192286","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530192286?lang=zh_cn&edition=full","pubTime":"2025-04-25 14:19","pubTimestamp":1745561940,"startTime":"0","endTime":"0","summary":"荣昌生物获上百家机构调研，关注其核心管线开发进展。RC18、RC48国内外研发进展顺利，涉及多个治疗领域，公司财务状况有所改善，净亏损同比缩小。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042514241894e20b66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042514241894e20b66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09995","LU1969619763.USD","BK1161","BK1583","688331","BK1574","LU2328871848.SGD"],"gpt_icon":0},{"id":"2529603551","title":"荣昌生物04月24日主力净流入3785万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2529603551","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529603551?lang=zh_cn&edition=full","pubTime":"2025-04-24 15:20","pubTimestamp":1745479206,"startTime":"0","endTime":"0","summary":"04月24日, 荣昌生物股价涨8.02%，报收51.30元，成交金额3.62亿元，换手率4.47%，振幅7.54%，量比1.55。荣昌生物今日主力资金净流入3785万元，上一交易日主力净流出2225万元。该股近5个交易日上涨12.95%，主力资金累计净流入4885万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入1.35亿元，其中净流入天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424155554a464fea5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424155554a464fea5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2148510915.USD","LU1064130708.USD","LU1064131003.USD","688331","BK0239"],"gpt_icon":0},{"id":"2529649310","title":"荣昌生物：多项成果股价涨 8.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529649310","media":"和讯网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529649310?lang=zh_cn&edition=full","pubTime":"2025-04-24 12:21","pubTimestamp":1745468505,"startTime":"0","endTime":"0","summary":"【荣昌生物早盘股价上涨，多项临床进展受关注】荣昌生物早盘一度涨超 12%，截至发稿，股价上涨 8.50%，报 38.30 港元，成交额 3.34 亿港元。美国临床肿瘤学会 2025 年年会将于 5 月 30 日至 6 月 3 日在美国芝加哥举行，荣昌生物 20 余项肿瘤管线临床进展或阶段性数据入选相关展示，包括维迪西妥单抗联合疗法等临床研究。近日荣昌生物于美国神经病学学会年会现场公布泰它西普用于治疗全身型重症肌无力中国 3 期试验结果，98.1%患者重症肌无力日常活动评分改善≥3 分，交银国际认为，泰它西普 gMGIII 期数据优于已上市竞品，且商业化推广策略清晰。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042413265494e086c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042413265494e086c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09995","LU2328871848.SGD","688331","BK1161","LU1969619763.USD","BK1583","BK1574"],"gpt_icon":0},{"id":"2529175146","title":"港股异动 | 荣昌生物(09995)一度涨超12% 维迪西妥单抗一线治疗胃癌结果入选2025 ASCO口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2529175146","media":"智通财经网","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529175146?lang=zh_cn&edition=full","pubTime":"2025-04-24 11:11","pubTimestamp":1745464260,"startTime":"0","endTime":"0","summary":"荣昌生物一度涨超12%，截至发稿，涨7.79%，报38.05港元，成交额2.98亿港元。消息面上，美国临床肿瘤学会2025年年会将于5月30日至6月3日在美国芝加哥举行。值得一提的是，近日荣昌生物于美国神经病学学会年会现场以口头报告形式公布泰它西普用于治疗全身型重症肌无力中国3期试验结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-24/doc-ineufstc3071321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1583","688331","LU1064130708.USD","LU2148510915.USD","LU1969619763.USD","BK1574","09995","BK0239","LU1064131003.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2529613897","title":"荣昌生物(09995)上涨10.76%，报39.1元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2529613897","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529613897?lang=zh_cn&edition=full","pubTime":"2025-04-24 09:54","pubTimestamp":1745459654,"startTime":"0","endTime":"0","summary":"4月24日，荣昌生物(09995)盘中上涨10.76%，截至09:54，报39.1元/股，成交1.62亿元。荣昌生物制药(烟台)股份有限公司的主营业务是发现、开发、生产和商业化同类首创、同类最佳的生物药物，主要针对自身免疫、肿瘤、眼科等重大疾病领域。公司在中国和美国设有实验研究机构和办事处，已创制出一批具有重大临床价值的生物新药。截至2024年年报，荣昌生物营业总收入17.1亿元、净利润-14.68亿元。4月28日，荣昌生物将披露2025财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/24095449815751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1064130708.USD","LU2148510915.USD","BK1161","688331","LU1969619763.USD","BK1583","BK1574","LU1064131003.USD","BK0239","LU2328871848.SGD","09995"],"gpt_icon":0},{"id":"2529618565","title":"【港股创新药板块盘初拉升，凯莱英涨超9%】港股创新药板块盘初拉升，凯莱英涨超9%，荣昌生物涨超7%，信达生物、君实生物、康龙化成纷纷上扬。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529618565","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529618565?lang=zh_cn&edition=full","pubTime":"2025-04-24 09:41","pubTimestamp":1745458866,"startTime":"0","endTime":"0","summary":"港股创新药板块盘初拉升，凯莱英涨超9%，荣昌生物涨超7%，信达生物、君实生物、康龙化成纷纷上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/24094149815242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06821","LU2148510915.USD","BK1141","159992","BK1191","06978","YANG","BK1583","BK1576","LU1969619763.USD","BK0239","BK1574","01877","BK1515","688180","03759","LU1328615791.USD","BK1589","LU2328871848.SGD","300759","09995","BK0132","HSTECH","BK4614","002821","LU1064131003.USD","LU2488822045.USD","BK1161","BK0216","LU1064130708.USD","688331","01801"],"gpt_icon":0},{"id":"2529690207","title":"荣昌生物涨5% 近半年6家券商买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2529690207","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529690207?lang=zh_cn&edition=full","pubTime":"2025-04-24 09:36","pubTimestamp":1745458617,"startTime":"0","endTime":"0","summary":"04月24日，荣昌生物股价大幅上涨，截至09点36分，荣昌生物上涨5.03%，报49.88元/股，成交4856万元，换手率0.61%。此外，数据统计显示，近半年内6家券商给予买入建议，3家券商给予中性建议。资金动向截止发稿，荣昌生物获得主力净流入502万元，其中超大单流入304万元，大单流入197万元。最新财报显示，今年年报，荣昌生物实现营业收入17.17亿元，同比增长58.54%，净利润为-14.68亿元，同比增长2.84%，基本每股收益为-2.73元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504240937239742d4f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504240937239742d4f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064130708.USD","LU2148510915.USD","LU1064131003.USD","688331","BK0239"],"gpt_icon":0},{"id":"2529864934","title":"2025 ASCO｜荣昌生物维迪西妥单抗一线治疗胃癌结果入选口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2529864934","media":"荣昌生物","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529864934?lang=zh_cn&edition=full","pubTime":"2025-04-24 08:30","pubTimestamp":1745454643,"startTime":"0","endTime":"0","summary":"REMEGEN美国临床肿瘤学会2025年年会将于5月30日至6月3日在美国芝加哥举行。ASCO年会是全球肿瘤医学领域最具权威性和影响力的学术盛会之一，每年汇聚来自世界各地的顶尖临床与科研成果。在本次大会上，荣昌生物20余项肿瘤管线临床进展或阶段性数据入选口头报告、壁报或线上展示，其中包括维迪西妥单抗联合疗法一线治疗HER2表达胃癌、维迪西妥单抗联合RC148一线治疗三阴性乳腺癌、RC108联合TKI二线治疗EFGR突变伴MET过表达非小细胞肺癌等临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424132154a464d6ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424132154a464d6ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","BK1161","688331","LU2328871848.SGD","09995","LU1969619763.USD"],"gpt_icon":0},{"id":"2529367183","title":"【港股医药股走强 歌礼制药涨近18%】截至发稿，歌礼制药-B(01672.HK)涨17.81%、荣昌生物(09995.HK)涨10.06%、映恩生物-B(09606.HK)涨9%、来凯生物-B(02105.HK)涨8.25%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529367183","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529367183?lang=zh_cn&edition=full","pubTime":"2025-04-22 09:55","pubTimestamp":1745286903,"startTime":"0","endTime":"0","summary":"截至发稿，歌礼制药-B(01672.HK)涨17.81%、荣昌生物(09995.HK)涨10.06%、映恩生物-B(09606.HK)涨9%、来凯生物-B(02105.HK)涨8.25%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/22095549737746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02105","LU2328871848.SGD","LU1064131003.USD","LU2148510915.USD","159718","09995","01477","01672","688331","BK1574","BK1583","BK0239","BK1515","LU1064130708.USD","LU1969619763.USD","BK1191","BK1161"],"gpt_icon":0},{"id":"2529362752","title":"港股创新药板块走强，歌礼制药(01672.HK)涨超20%，荣昌生物(09995.HK)、石药集团(01093.HK)涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2529362752","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529362752?lang=zh_cn&edition=full","pubTime":"2025-04-22 09:49","pubTimestamp":1745286560,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["07226","LU0501845795.SGD","06160","LU1807302812.USD","BK0239","LU0307460666.USD","LU1152091168.USD","BK4139","09995","BK1515","YANG","IE0008368742.USD","01093","BK1161","BK1521","BK1588","BK1583","IE0008369823.USD","LU2328871848.SGD","LU1226288170.HKD","IE00B031HY20.USD","IE00B543WZ88.USD","LU0880133367.SGD","LU1226287792.SGD","LU1152091754.HKD","LU1226287529.USD","HSCEI","01477","06978","LU0140636845.USD","159992","01672","BK1574","LU1226288253.USD","LU2488822045.USD","01801","LU1993786604.SGD","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK4614","LU1951186391.HKD","ONC","IE00B5MMRT66.SGD","LU1969619763.USD","SG9999004220.SGD","688235","HSTECH","LU1008478684.HKD","688331","BK1500"],"gpt_icon":0},{"id":"2529081270","title":"荣昌生物涨5% 无CDMO业务计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2529081270","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529081270?lang=zh_cn&edition=full","pubTime":"2025-04-21 10:22","pubTimestamp":1745202154,"startTime":"0","endTime":"0","summary":"04月21日，荣昌生物股价大幅上涨，截至10点22分，荣昌生物上涨5.03%，报47.39元/股，成交1.00亿元，换手率1.34%，振幅6.12%。消息解读荣昌生物在互动平台表示，公司目前没有开展CDMO业务的计划；对于国际BD的谈判，公司将会根据进展情况，严格按照相关法律法规，及时履行信息披露义务。资金动向截止发稿，荣昌生物获得主力净流入605万元，其中超大单流入592万元，大单流入12万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250421102351a46060dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250421102351a46060dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2148510915.USD","LU1064130708.USD","688331","LU1064131003.USD","BK0239"],"gpt_icon":0},{"id":"2528056395","title":"荣昌生物：没有开展CDMO业务的计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2528056395","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528056395?lang=zh_cn&edition=full","pubTime":"2025-04-18 16:06","pubTimestamp":1744963613,"startTime":"0","endTime":"0","summary":"格隆汇4月18日丨荣昌生物(688331.SH)在互动平台表示，公司目前没有开展CDMO业务的计划；对于国际BD的谈判，公司将会根据进展情况，严格按照相关法律法规，及时履行信息披露义务，具体请您以公司法定平台披露的内容为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250418160653a6bf09b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250418160653a6bf09b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064130708.USD","688331","LU2148510915.USD","BK0239","LU1064131003.USD"],"gpt_icon":0},{"id":"2528825034","title":"荣昌生物：对于您提及的ADC联合疗法目前公司针对RC48与PD-1抑制剂的联合疗法已有适应症启动全球多中心临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2528825034","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528825034?lang=zh_cn&edition=full","pubTime":"2025-04-18 15:57","pubTimestamp":1744963029,"startTime":"0","endTime":"0","summary":"证券之星消息，荣昌生物04月18日在投资者关系平台上答复投资者关心的问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025041800021394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","09995","BK0239","BK1161","LU1064131003.USD","LU1064130708.USD","LU2328871848.SGD","BK1583","LU1969619763.USD","LU2148510915.USD","688331"],"gpt_icon":0},{"id":"2528034892","title":"荣昌生物：公司会定期对研发管线进行全面评估","url":"https://stock-news.laohu8.com/highlight/detail?id=2528034892","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528034892?lang=zh_cn&edition=full","pubTime":"2025-04-18 15:57","pubTimestamp":1744963025,"startTime":"0","endTime":"0","summary":"证券之星消息，荣昌生物(688331)04月18日在投资者关系平台上答复投资者关心的问题。投资者提问：研发管线聚焦（如RC88、RC108等）是否将缩减非核心项目，集中资源推进高潜力靶点以提升资本效率？荣昌生物回复：尊敬的投资者，您好！公司会定期对研发管线进行全面评估，通过对靶点的潜力、临床前及临床试验数据、市场前景等多方面因素审慎决策，具体管线布局情况请您以公司法定平台披露的公告为准，感谢您的关注与支持！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025041800021385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","LU2148510915.USD","09995","LU1064130708.USD","LU1969619763.USD","LU1064131003.USD","LU2328871848.SGD","BK1583","BK1161","BK1574","BK0239"],"gpt_icon":0},{"id":"2528034801","title":"荣昌生物：公司将通过提高研发效率，平衡研发投入与盈利目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2528034801","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528034801?lang=zh_cn&edition=full","pubTime":"2025-04-18 15:57","pubTimestamp":1744963024,"startTime":"0","endTime":"0","summary":"证券之星消息，荣昌生物04月18日在投资者关系平台上答复投资者关心的问题。期待公司以明确里程碑和商业化路径，强化投资者对业绩放量的预期，驱动价值重估。感谢您的关注和建议，公司将通过提高研发效率，平衡研发投入与盈利目标，对于国际合作公司一直秉持开放的态度，公司将会根据进展情况，严格按照相关法律法规，及时履行信息披露义务，感谢您的关注！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025041800021380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","BK1583","LU2328871848.SGD","LU1064130708.USD","LU1064131003.USD","BK0239","LU1969619763.USD","09995","BK1161","LU2148510915.USD","BK1574"],"gpt_icon":0},{"id":"2528797272","title":"荣昌生物收盘下跌1.07%，最新市净率12.45，总市值247.24亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528797272","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528797272?lang=zh_cn&edition=full","pubTime":"2025-04-17 18:53","pubTimestamp":1744887209,"startTime":"0","endTime":"0","summary":"4月17日，荣昌生物今日收盘45.42元，下跌1.07%，最新市净率12.45，总市值247.24亿元。截至2024年年报，共有265家机构持仓荣昌生物，其中基金262家、其他3家，合计持股数9245.91万股，持股市值27.84亿元。最新一期业绩显示，2024年年报，公司实现营业收入17.17亿元，同比58.54%；净利润-1468360802.55元，同比2.84%，销售毛利率80.36%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/17185349628032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688331","LU2148510915.USD","09995","LU1064130708.USD","LU1969619763.USD","LU1064131003.USD","LU2328871848.SGD","BK1583","BK1161","BK1574","BK0239"],"gpt_icon":0},{"id":"2527266700","title":"荣昌生物04月16日主力净流出3220万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2527266700","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527266700?lang=zh_cn&edition=full","pubTime":"2025-04-16 15:21","pubTimestamp":1744788112,"startTime":"0","endTime":"0","summary":"04月16日, 荣昌生物股价跌3.81%，报收45.91元，成交金额2.92亿元，换手率3.90%，振幅7.21%，量比0.71。荣昌生物今日主力资金净流出3220万元，上一交易日主力净流入1768万元。该股近5个交易日上涨4.34%，主力资金累计净流入4549万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入8106万元，其中净流入天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416170634a45adff0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416170634a45adff0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","LU2148510915.USD","LU1064130708.USD","688331","LU1064131003.USD"],"gpt_icon":0},{"id":"2527253500","title":"港股异动 | 荣昌生物(09995)再涨超4% 月底将披露一季度业绩 泰它西普三期MG数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2527253500","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527253500?lang=zh_cn&edition=full","pubTime":"2025-04-16 15:17","pubTimestamp":1744787844,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物再涨超4%，月内股价已累涨超四成。截至发稿，涨4.79%，报35港元，成交额3.45亿港元。消息面上，荣昌生物宣布将于4月28日发布一季度业绩。此外，近日公司于美国神经病学学会年会现场以口头报告形式公布泰它西普用于治疗全身型重症肌无力中国3期试验结果。交银国际认为，泰它西普gMGIII期数据优于已上市竞品，且商业化推广策略清晰。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1279416.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","LU1064130708.USD","IE00B66KJ199.SGD","LU1969619763.USD","LU2148510915.USD","BK1574","IE0031619046.USD","IE00B7SZL793.SGD","LU1064131003.USD","IE00B19Z4B17.USD","MG","BK4123","BK1161","BK1583","688331","BK0239","LU2328871848.SGD"],"gpt_icon":0},{"id":"2527282334","title":"荣昌生物大跌5% 近半年6家券商买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2527282334","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527282334?lang=zh_cn&edition=full","pubTime":"2025-04-16 11:19","pubTimestamp":1744773545,"startTime":"0","endTime":"0","summary":"04月16日，荣昌生物股价大幅下跌，截至11点19分，荣昌生物下跌5.05%，报45.32元/股，成交1.65亿元，换手率2.18%。此外，数据统计显示，近半年内6家券商给予买入建议，2家券商给予中性建议。资金动向截止发稿，荣昌生物获得主力净流出910万元，其中超大单流出2353万元，大单流入1444万元。最新财报显示，今年年报，荣昌生物实现营业收入17.17亿元，同比增长58.54%，净利润为-14.68亿元，同比增长2.84%，基本每股收益为-2.73元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041611191897395d58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041611191897395d58&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064131003.USD","LU1064130708.USD","BK0239","LU2148510915.USD","688331"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1745666924404,"stockEarnings":[{"period":"1week","weight":0.1538},{"period":"1month","weight":0.4526},{"period":"3month","weight":0.8666},{"period":"6month","weight":0.7074},{"period":"1year","weight":-0.0584},{"period":"ytd","weight":0.729}],"compareEarnings":[{"period":"1week","weight":0.0056},{"period":"1month","weight":-0.0219},{"period":"3month","weight":0.013},{"period":"6month","weight":-0.0014},{"period":"1year","weight":0.0793},{"period":"ytd","weight":-0.0169}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"荣昌生物制药(烟台)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"6693人(较上一季度增加2.56%)","perCapita":"24196股","listingDate":"2022-03-31","address":"山东省烟台市福山区中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号","registeredCapital":"54433万元","survey":" 荣昌生物制药(烟台)股份有限公司的主营业务是开发与商业化创新、有特色的同类首创（first-in-class）与同类最佳（best-in-class）生物药，以创造药物临床价值为导向，为自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域提供安全、有效、可及的临床解决方案，以满足大量尚未被满足的临床需求。公司的主要产品是泰它西普（RC18）、维迪西妥单抗（RC48）、RC28、RC88、RC148、RC278。","listedPrice":48},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,688331,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}